Our clinical study, Evaluation of Cultured Expanded Allogeneic, Cord-Derived Mesenchymal Stem Cells, Deployed via Intravenous Injection for Safety and Effect on Systemic Inflammation, is registered with the government of the Cayman Islands (Trial HPC/CTr/003). Our cells are ethically sourced from AATB certified, US-donated, full term human umbilical cords and processed in our award-winning partner medical laboratory located in the USA, which is fully FDA registered, cGMP compliant, ISO 9001, and ISO 13485 certified. The cells are tested for viability to ensure they meet minimum QA requirements multiple times before treatment. Our IRB-approved protocol consists of a two-day period including the intravenous (IV) administration of 300 million culturally expanded human umbilical cord tissue-derived adult mesenchymal stem cells (MSCs).
Our clinical study, Evaluation of Cultured Expanded Allogeneic, Cord-Derived Mesenchymal Stem Cells, Deployed via Intravenous Injection for Safety and Effect on Systemic Inflammation, is registered with the government of the Cayman Islands (Trial HPC/CTr/003). Our cells are ethically sourced from AATB certified, US-donated, full term human umbilical cords and processed in our award-winning partner medical laboratory located in the USA, which is fully FDA registered, cGMP compliant, ISO 9001, and ISO 13485 certified. The cells are tested for viability to ensure they meet minimum QA requirements multiple times before treatment. Our IRB-approved protocol consists of a two-day period including the intravenous (IV) administration of 300 million culturally expanded human umbilical cord tissue-derived adult mesenchymal stem cells (MSCs).